Screening showed that F1 had more significant and balanced immunomodulatory effects on DCs when compared to the other fractions (F2 and F3), inducing a mature profile characterized by increased surface markers, enhanced TNF-α release and moderate IL-1β (which is a cytokine with pleiotropic effects on immune cells, angiogenesis, cancer cell proliferation, migration, and metastasis) and IL-10, in association with a classical activated morphological profile. The gene discussed is TNF; the disease is cancer.